# Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
Canonical URL: https://biopharmsignal.com/news/RLYB/rallybio-corporation-and-avenzo-therapeutics-announce-merger-agreement-to-advance-next-generation-oncology-therapies-and-215-million-concurrent-private-placement
Ticker: RLYB
Company: Rallybio
Source: Rallybio
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.rallybio.com
## Summary

Combined company to operate as Avenzo Therapeutics, advancing a leading portfolio of next-generation oncology therapies, including small molecules and antibody-drug conjugates Concurrent oversubscribed private placement financing of $215 million with participation from leading syndicate of

## Article Body
Combined company to operate as Avenzo Therapeutics, advancing a leading portfolio of next-generation oncology therapies, including small molecules and antibody-drug conjugates Concurrent oversubscribed private placement financing of $215 million with participation from leading syndicate of
## Recent Company News
- 2026-06-25 13:46 EST — [Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement](https://biopharmsignal.com/news/RLYB/rallybio-corporation-and-avenzo-therapeutics-announce-merger-agreement-to-advance-next-generation-oncology-therapies-and-215-million-concurrent-private-placement) — Source: Rallybio
- 2026-06-25 13:46 EST — [Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/RLYB/rallybio-reports-first-quarter-2025-financial-results-and-provides-business-updates) — Source: Rallybio
- 2026-06-25 13:46 EST — [Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study](https://biopharmsignal.com/news/RLYB/rallybio-initiates-dosing-in-rlyb116-phase-1-confirmatory-pharmacokinetic-pharmacodynamic-study) — Source: Rallybio
- 2026-06-25 13:46 EST — [Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals](https://biopharmsignal.com/news/RLYB/rallybio-sells-interest-in-rev102-program-to-recursion-pharmaceuticals) — Source: Rallybio
- 2026-06-25 13:46 EST — [Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/RLYB/rallybio-reports-second-quarter-2025-financial-results-and-provides-business-updates) — Source: Rallybio
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)